Connect with us

Technology

ISS National Lab Enables Record-Breaking Year of Space-Based Scientific Results

Published

on

More than 50 peer-reviewed articles published in fiscal year 2024, bringing all-time number to nearly 450

KENNEDY SPACE CENTER, Fla., Jan. 9, 2025 /PRNewswire/ — The International Space Station (ISS) National Laboratory pushed scientific boundaries and set a record in scholarly output over the past year. Results from these investigations address real-world challenges and benefit Earth’s economy.

In fiscal year 2024 (October 1, 2023-September 30, 2024), more than 50 peer-reviewed articles related to ISS National Lab-sponsored research were published, bringing the all-time number to nearly 450. These findings lay a robust foundation for ongoing scientific advancements that promise significant benefits for humanity. Several groundbreaking results were featured in three new issues of Upward, official magazine of the ISS National Lab, highlighting the broad impact of research in space to improve the lives of people on Earth.

The following list details some of the most transformative investigations, underscoring their potential to drive further innovation and valuable applications.  

Top ISS National Lab-Related Scientific Results Highlighted in 2024

      1. Biomedical Advances: 3D Printing of Human Heart Tissue

Redwire Corporation utilized its BioFabrication Facility (BFF) on the ISS to 3D print live human heart tissue. This achievement moves us closer to producing complex human tissues in space to treat damaged tissue in people on Earth, potentially revolutionizing medical treatments for many conditions.

       2. Materials Science: Manufacturing Optical Fibers

Flawless Photonics produced more than 11 kilometers of ZBLAN optical fiber onboard the ISS, including a record-setting single pull that was more than a kilometer long. This production showcases the potential for creating superior optical fibers in microgravity, which could enhance telecommunications and medical technologies on Earth.

       3. Global Monitoring: Advanced Hyperspectral Imaging

Orbital Sidekick validated its cutting-edge hyperspectral imaging technology to monitor ecological changes and potential environmental disasters from space. This validation was a crucial step for the company to offer real-time global monitoring services that provide customers with a powerful tool to solve their most pressing challenges.

       4. Agricultural Innovations: Genetic Studies in Microgravity

Clemson University research into cotton genetics under microgravity conditions uncovered new methods to enhance crop resilience and productivity, with potential applications that could benefit global agricultural practices.

       5. Neurological Insights: Studying Brain Organoids

Axonis Therapeutics grew brain organoids in space to test a new therapeutic for neurological conditions like Alzheimer’s, Parkinson’s, and spinal cord injury. The ability to self-assemble brain organoids from mature cells in space in just a few days compared to months on Earth highlights the unique benefits microgravity offers for biological research.

       6. Educational Outreach: ISS Mimic by Creatorspace

ISS Mimic, an educational product developed by Creatorspace, allows students to build a 1:100 scale model of the ISS that mimics the real-time movements of the space station using actual telemetry data. This product aims to enhance science, technology, engineering, and mathematics (STEM) education in schools, libraries, and museums.

       7. Fluid Dynamics Research: Bubbles Behavior Study 

An experiment from researchers at the University of Notre Dame investigated the fluid dynamics of bubble formation in microgravity. The research sought to gain a better understanding of how bubbles form and grow to improve biosensors that could be used for early and asymptomatic cancer detection.

       8. AstroRad: A Wearable Radiation Shield 

Tested by crew members on the ISS, the AstroRad vest is designed to protect astronauts from radiation during missions to the Moon and Mars. Feedback from the tests led to design tweaks improving the vest’s fit and mobility, enhancing astronaut safety.

       9. Orbital Oncology: 3D Tumor Cell Cultures in Space

MicroQuin grew 3D cultures of breast and prostate cancer cells in microgravity to better understand cancer cell behavior. The findings provided significant insights into cancer cell survival mechanisms and could lead to a therapeutic to treat all types of cancer.

       10. Preventing Post-Traumatic Osteoarthritis: Tissue Chips Studies in Microgravity

A Massachusetts Institute of Technology (MIT) study explored the potential of utilizing tissue chips in space to better understand the underlying causes of post-traumatic osteoarthritis (PTOA). The findings provided valuable insights into the biological mechanisms of PTOA, potentially leading to innovative therapeutic strategies.

       11. Testing New Technology: Astrobee Robots on Station

NASA’s free-flying Astrobee robots on the ISS have assisted with more than 150 investigations, many of which were sponsored by the ISS National Lab. One such project tested specialized microphone technology designed to identify anomalies in equipment by interpreting changes in sound. Another tested a new method to rendezvous with tumbling objects in space for satellite recovery efforts. The Astrobees are also helping inspire the next generation of scientists through MIT’s Zero Robotics program.

Laying the Groundwork for Future Innovation 
Results from ISS National Lab-sponsored investigations reflect the value of leveraging the unique environment of space to conduct high-impact research that cannot be replicated on Earth. These efforts advance our understanding of fundamental science and drive innovations that address practical challenges across healthcare, technology development, and beyond.

For detailed information and behind-the-scenes stories on results from ISS National Lab-sponsored investigations, subscribe to Upward. 

Download a high-resolution image for this release: Nanoracks External Platform 

About the International Space Station (ISS) National Laboratory:
The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space™ (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.

As a 501(c)(3) nonprofit organization, CASIS® accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.

Media Contact:

Patrick O’Neill 

904-806-0035

PONeill@ISSNationalLab.org  

 

International Space Station (ISS) National Laboratory

Managed by the Center for the Advancement of Science in Space, Inc. (CASIS)

1005 Viera Blvd., Suite 101, Rockledge, FL 32955 • 321.253.5101 • www.ISSNationalLab.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/iss-national-lab-enables-record-breaking-year-of-space-based-scientific-results-302347261.html

SOURCE International Space Station National Lab

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

COHEN & STEERS REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024

Published

on

By

NEW YORK, Jan. 22, 2025 /PRNewswire/ — Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the fourth quarter and year ended December 31, 2024. The earnings release along with the accompanying earnings presentation can be viewed at Cohen & Steers Reports Results for Fourth Quarter and Year Ended December 31, 2024 and on the company’s website at www.cohenandsteers.com under “Company—Investor Relations—Earnings Archive.”

Conference Call

The company will host a conference call tomorrow, Thursday, January 23, 2025, at 10:00 a.m. (ET) to discuss these results via webcast and telephone. Hosting the call will be chief executive officer, Joseph Harvey, chief financial officer, Raja Dakkuri, and head of multi-asset solutions, Jeffrey Palma.

Investors and analysts can access the live conference call by dialing 800-715-9871 (U.S.) or +1-646-307-1963 (international); passcode: 8494569. Participants should plan to register at least 10 minutes before the conference call begins. A replay of the call will be available for two weeks starting approximately two hours after the conference call concludes and can be accessed at 800-770-2030 (U.S.) or +1-609-800-9909 (international); passcode: 8494569. Internet access to the webcast, which includes audio (listen-only), will be available on the company’s website at www.cohenandsteers.com under “Company—Investor Relations” under “Financials.” The webcast will be archived on the website for one month.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

View original content:https://www.prnewswire.com/news-releases/cohen–steers-reports-results-for-fourth-quarter-and-year-ended-december-31-2024-302357884.html

SOURCE Cohen & Steers, Inc.

Continue Reading

Technology

Equifax Announces Earnings Release Date and Conference Call for Fourth Quarter 2024 Results

Published

on

By

ATLANTA, Jan. 22, 2025 /PRNewswire/ — Equifax® (NYSE: EFX) will announce its financial results for the fourth quarter ended December 31, 2024, in a release to be issued on Thursday, February 6, at 6:30 a.m. Eastern Time (ET).

Equifax will host a conference call at 8:30 a.m. ET on February 6, in which senior management will discuss financial and business results for the quarter. Related presentation materials will be published on investor.equifax.com on February 6 at 6:30 a.m. ET.

Conference Call:  
US/Canada: 877-559-1190 / +1 201-389-0916
International: Click here for participant International Toll-Free access numbers

Please dial the appropriate number 5-10 minutes prior to the call to complete registration. Name and affiliation/company are required to join the call.

Webcast:
To view the webcast and slide presentation, please click the link and enter your information to be connected. The link becomes active 15 minutes prior to the scheduled start time.

An audio replay of the conference call will be available on investor.equifax.com beginning on February 7.

ABOUT EQUIFAX INC.
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.com.

FOR MORE INFORMATION:
Molly Clegg for Equifax
molly.clegg@equifax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/equifax-announces-earnings-release-date-and-conference-call-for-fourth-quarter-2024-results-302357665.html

SOURCE Equifax Inc.

Continue Reading

Technology

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

Published

on

By

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 22, 2025 /PRNewswire/ — Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic unification under a single ownership. 

This consolidation creates a vertically integrated Synthetic Biology and Biomanufacturing powerhouse, uniquely positioned to harness the disruptive potential of precision fermentation. By integrating decades of expertise, the unified organization will leverage the strength of each team to seamlessly advance Synthetic Biology innovation from ideation to commercial production.

The acquisitions bring together over 100 engineers, scientists, and seasoned biotech executives, marking a significant leap forward in the rapidly evolving biomanufacturing landscape. The unified organization is fully equipped to give clients unparalleled and seamless support in all stages of biomanufacturing, including microbial strain and bioprocess development, plant engineering, automation, construction, deployment, and large-scale operations. The coming months will involve further integrational activities to fully leverage the strength of the organization.

Strategic Relevance

“The challenges of microbial strain engineering often hindered by restrictive intellectual property and the technical hurdles of scaling bioprocesses, have long impeded the faster development of synthetic biology products. By uniting these companies, we can directly address these challenges head-on, transforming the biomanufacturing landscape with the financial and operational support necessary for growth,” said Alex Berlin, CEO of Pictor Biotech Inc. (d.b.a. SOLARBIOTECH).

Zsolt Popsé, CEO of GPC Bio, added, “With nearly 20 years of experience in designing, engineering, automating, and deploying biomanufacturing equipment, we have delivered world-class facilities for leading biopharmaceutical companies such as Merck, Sanofi, and Millipore-Sigma, as well as major food and beverage companies like Cargill, Groupe Soufflet, and Lesaffre. The integration of GPC Bio with EG and SOLARBIOTECH places us in a unique position to mitigate risk and accelerate growth in the biomanufacturing space.”

Lóránd Szabó, Managing Director of Eleszto Genetika Kft., stated, “Over the past two decades, we have developed hundreds of microbial strains for the production of biopharmaceuticals, nutraceuticals, and cosmeceuticals. By joining forces with Solar Biotech and GPC Bio, we can efficiently transition products from laboratory scale to commercial production, overcoming the typical hurdles faced by non-integrated organizations.”

Peter Rosholm, owner of EG, GPC Bio and Pictor Biotech (dba SOLARBIOTECH) emphasized: “I am fully committed to investing in and to accelerate the commercial development of sustainable biomanufacturing technologies. By combining SOLARBIOTECH, GPC Bio, and EG under one umbrella, we are uniquely positioning our teams to thrive in this rapidly growing sector. We have a strong, client-focused and diverse organization with very experienced management, and this commitment adds significant funding to the existing companies’ infrastructure.”

About the Companies

Executive Management of the three companies will continue to serve in their respective leadership roles. Peter Rosholm will exclusively serve the organization from an owner and investor capacity.

SOLARBIOTECH (“SBC”), based in Norton, VA, USA, offers world-class expertise in microbial and animal and plant cell precision fermentation and downstream processing across various scales. Leveraging 18 acres of industrial park infrastructure in Southwest Virginia, SBC consistently delivers innovative synthetic biology bioprocesses and products for its partners. 

GPC Bio (“GPC”), headquartered in La Rochelle, France, specializes in the design, automation, software control, engineering, and fabrication of biomanufacturing equipment for the biopharmaceutical, food tech, and beverage industries. For nearly two decades, GPC Bio has delivered state-of-the-art systems to some of the biggest names in industrial biotech and biopharma.

Eleszto Genetika Kft. (“EG”), based in Budapest, Hungary, brings nearly two decades of expertise in R&D for advanced industrial microbial strains. EG’s portfolio includes microbial strains from engineered yeasts, bacteria, and filamentous fungi for producing a wide range of biopharmaceuticals, nutraceuticals, and cosmeceuticals, supported by cutting-edge infrastructure in the heart of the European Union.

For Further Information, Please Contact:

Alex Berlin, CEO & CTO, Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), alex@solarbiotech.com, www.solarbiotech.comZsolt Popsé, CEO of GPC Bio, z.popse@gpcbio.comwww.gpcbio.comLóránd Szabó, Managing Director, Eleszto Genetika Kft., lszabo@elesztogenetika.com, www.elesztogenetika.com

View original content:https://www.prnewswire.com/news-releases/pictor-biotech-inc-dba-solarbiotech-gpc-bio-and-eleszto-genetika-announce-strategic-unification-302357893.html

SOURCE Pictor Biotech Inc. (dba SOLARBIOTECH), GPC Bio, and Eleszto Genetika

Continue Reading

Trending